LRRK2 and Parkinson disease: DNL151 (also known as BIIB122), an orally administered LRRK2 inhibitor, has passed phase 1 and its disease-modifying efficacy is currently evaluated in PD patients with known LRRK2 mutation in up to 180 weeks (NCT05418673) and sporadic PD patients without LRRK2 mutation in up to 144 weeks (NCT05348785).